Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients-Reference-Cited by-同舟云学术

Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients

Published:2018-05-14 Issue:10 Volume:2 Page:1066-1075
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Yoshioka Hideki¹,Sato Hiromi¹,Hatakeyama Hiroto¹,Hisaka Akihiro¹

Affiliation:

1. Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan

Abstract

Key Points Simulations suggested that the dose reduction of rivaroxaban would decrease fatal events associated with major bleeding. Dose optimization of FXa inhibitors might further enhance their therapeutic benefit.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/10/1066/879904/advances013805.pdf

Reference51 articles.

1. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2014;130(23):e270-e271];January;Circulation,2014

2. Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation;Cabral;Nat Rev Cardiol,2012

3. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

4. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N Engl J Med,2011

5. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk　― Reply ―;Circulation Journal;2022-06-24

2. A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation;Frontiers in Pharmacology;2022-03-18

3. Applications of Model-Based Meta-Analysis in Drug Development;Pharmaceutical Research;2022-02-16

4. Pharmacometrics meets statistics—A synergy for modern drug development;CPT: Pharmacometrics & Systems Pharmacology;2021-08-19

5. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis;European Journal of Clinical Pharmacology;2020-05-25